Related Experiment Video

Updated: Nov 23, 2025

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

2.0K

PARP inhibitors in ovarian cancer: An overview of the practice-changing trials

Tiffany Foo1,2, Angela George1,2, Susana Banerjee1,3

  • 1Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK.

Genes, Chromosomes & Cancer
|December 31, 2020
PubMed

Insights

Poly (ADP-ribose) polymerase (PARP) inhibitors are now standard first-line maintenance therapy for advanced ovarian cancer, especially in patients with BRCA mutations. This review covers key trials, biomarker use, and future directions for PARP inhibitors in gynecological cancers.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Poly (ADP-ribose) polymerase (PARP) inhibitors have revolutionized ovarian cancer treatment.
  • Olaparib established a new standard of care as maintenance therapy for BRCA-mutated ovarian cancer.
  • Three PARP inhibitor strategies are now approved for first-line maintenance therapy.

Purpose of the Study:

  • To review pivotal PARP inhibitor trials in ovarian cancer.
  • To discuss biomarker-directed therapy using BRCA and homologous recombination deficiency (HRD) status.
  • To explore future applications of PARP inhibitors in gynecological malignancies.

Main Methods:

  • Review of phase III clinical trials (SOLO1, PRIMA, PAOLA-1).
  • Analysis of biomarker status (BRCA mutations, HRD).
  • Discussion of clinical practice changes and future strategies.

Main Results:

  • PARP inhibitors have significantly improved outcomes in ovarian cancer management.
  • First-line maintenance therapy with PARP inhibitors is now an established standard of care.
  • Biomarker status is crucial for directing PARP inhibitor therapy.

Conclusions:

  • PARP inhibitors represent a major advancement in ovarian cancer treatment.
  • The use of PARP inhibitors is expanding to other gynecological cancers.
  • Personalized therapy based on biomarkers is key for optimizing treatment outcomes.
Keywords:
BRCAHRDPARP inhibitorsmaintenance therapyovarian cancer

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.3K